Mineral Forms · Mineral
Chromium Heptoxide
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Chromium heptoxide (CrO3, also called chromium trioxide) is a highly toxic industrial oxidizing agent, not a dietary supplement or therapeutic compound. It is classified as a Group 1 human carcinogen by the IARC due to its hexavalent chromium content, which causes DNA damage and severe tissue destruction upon contact.
Chromium heptoxide (Cr₂O₇) or related chromium(VI) compounds like CrO₃ are synthetic inorganic compounds produced industrially by treating sodium chromate with sulfuric acid. These compounds have no natural origin, are not extracted from organisms or plants, and are manufactured solely for industrial applications like electroplating and oxidation.
No human clinical trials, RCTs, or meta-analyses exist for chromium heptoxide as a biomedical ingredient. Search results contain zero PubMed PMIDs or studies on therapeutic use; it is identified solely as a toxic industrial chemical and suspected carcinogen, not evaluated for clinical efficacy.
No clinically studied dosages exist for any form as chromium heptoxide lacks biomedical applications and is highly toxic. This compound is not for human consumption under any circumstances. Consult a healthcare provider before starting any new supplement.
Chromium heptoxide (CrO₃·CrO₃ or Cr₂O₇, often referenced as dichromium heptoxide) is a highly reactive, toxic chromium(VI) oxide compound. It has zero nutritional value. **Composition:** Exclusively chromium in the hexavalent (+6) oxidation state combined with oxygen; no macronutrients (0 g protein, 0 g fat, 0 g carbohydrate, 0 g fiber), no vitamins, and no beneficial bioactive compounds. **Chromium(VI) distinction:** Unlike trivalent chromium (Cr³⁺), which is an essential trace mineral involved in insulin signaling at ~25–35 µg/day adequate intake, hexavalent chromium (Cr⁶⁺) as found in chromium heptoxide is a powerful oxidizer classified by IARC as a Group 1 human carcinogen. It readily penetrates cell membranes via sulfate/phosphate anion transport channels, leading to intracellular reduction that generates reactive intermediates (Cr⁵⁺, Cr⁴⁺), oxygen radicals, and DNA adducts. **Bioavailability notes:** Cr⁶⁺ compounds are unfortunately highly bioavailable — readily absorbed through inhalation (primary occupational route), ingestion, and even dermal contact, which is precisely what makes them so hazardous. Gastrointestinal absorption of Cr⁶⁺ can be substantial compared to the ~0.5–2% absorption rate of nutritional Cr³⁺. **Toxicological profile per relevant exposure:** Causes severe chemical burns to mucous membranes, acute tubular necrosis in kidneys, hepatotoxicity, pulmonary edema upon inhalation, and confirmed mutagenicity/carcinogenicity (particularly lung and sinonasal cancers). OSHA PEL for Cr⁶⁺ compounds: 5 µg/m³ (airborne). **Summary:** This compound contains no nutrients, no beneficial minerals in usable form, and no bioactive compounds with therapeutic potential. It is universally contraindicated for any form of human consumption or supplementation.
Chromium heptoxide releases hexavalent chromium (Cr(VI)), which penetrates cell membranes via sulfate transport channels and is intracellularly reduced to Cr(III), generating reactive oxygen species including hydroxyl radicals and causing oxidative DNA strand breaks. This process inhibits DNA polymerase activity, crosslinks DNA-protein complexes, and triggers apoptotic and necrotic cell death cascades. Unlike nutritional trivalent chromium (Cr(III)), which modestly potentiates insulin receptor signaling, Cr(VI) from chromium heptoxide has no beneficial enzymatic or receptor interaction and exclusively causes cytotoxicity.
There are zero PubMed-indexed clinical trials, randomized controlled studies, or human intervention studies investigating chromium heptoxide for any therapeutic or nutritional purpose. Occupational and toxicological studies consistently document its role in causing lung cancer, nasal septum perforation, and acute kidney injury in exposed industrial workers. Case reports and poison control data confirm that ingestion or inhalation causes severe corrosive damage to respiratory mucosa, gastrointestinal tract hemorrhage, and multi-organ failure. The entire body of biomedical evidence classifies chromium heptoxide exclusively as an occupational hazard with no therapeutic benefit at any dose.
Chromium heptoxide is acutely lethal and corrosive; ingestion of as little as 1-2 grams has caused human fatalities due to gastrointestinal hemorrhage, hepatic failure, and acute renal tubular necrosis. Skin or inhalation exposure causes deep chemical burns, ulceration, and irreversible respiratory damage, with chronic low-level exposure strongly linked to squamous cell carcinoma of the lung. It has no established safe dose, no tolerable upper intake level, and is absolutely contraindicated in all populations including pregnant women, as Cr(VI) is fetotoxic and genotoxic. It has no known drug interactions relevant to supplementation because it has no legitimate use as a supplement.
